Cargando…

P19-28. The V3 region of HIV-1: from NMR to vaccine design

Detalles Bibliográficos
Autores principales:	Moseri, A, Naider, F, Anglister, J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767857/ http://dx.doi.org/10.1186/1742-4690-6-S3-P348

Ejemplares similares

P17-27. Development of recombinant adenovirus 28 vectors for HIV vaccines
por: Ko, S, et al.
Publicado: (2009)

P15-28. Attitudes and awareness of HIV vaccine research in HIV uninfected MSM in four US cities: Rochester, Boston, San Francisco and Philadelphia
por: Alexander, SB, et al.
Publicado: (2009)

P17-14. Fitness-informed HIV-1 Gag-p24 vaccine design
por: Rolland, MM, et al.
Publicado: (2009)

P16-28. The first year: early correlates of long-term HIV progression
por: Chattopadhyay, PK, et al.
Publicado: (2009)

P02-02. Analysis of antigen specific degranulation potentials using IL-12 or IL-28B during HIV DNA Vaccination
por: Morrow, M, et al.
Publicado: (2009)

P17-26. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success
por: De Groot, AS, et al.
Publicado: (2009)

P04-42. Molecular design of a mimotope that preserves conserved structural elements of the HIV-1 V3 crown
por: Jiang, X, et al.
Publicado: (2009)

NMR spectroscopy of HIV-1 gp120 outer domain
por: Sastry, M, et al.
Publicado: (2012)

P28. Resident Perspectives on Diversity and Inclusion
por: Means, Olivia, et al.
Publicado: (2022)

P19-32. HIV-1 vaccine design based on human vaccine trials to improve Gag, Pol, Nef and Env specific immune responses
por: Wild, J, et al.
Publicado: (2009)

P12-09. Immune responses in controlled and uncontrolled HIV infection to a designed HIV immunogen sequence focused on conserved regions of the viral genome
por: Mothe, B, et al.
Publicado: (2009)

P17-28 LB. The antiviral efficacy of HIV-specific CD8+ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate
por: Ranasinghe, S, et al.
Publicado: (2009)

P15-06. Brighton collaboration viral vector vaccines safety working group (V3SWG): maximizing the comparability and value of safety data from HIV vaccine trials
por: Chen, RT, et al.
Publicado: (2009)

P19-30. GTU(® )as beneficial HIV DNA vaccine vector system
por: Männik, A, et al.
Publicado: (2009)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

Assessing the protective efficacy of antibodies to the HIV gp41 region by active vaccination
por: Sharma, SK, et al.
Publicado: (2012)

P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda
por: Eller, L, et al.
Publicado: (2009)

P12-13. Structure-guided design and immunological characterization of immunogen constructs presenting the HIV-1 gp120 V3 loop on a CTB scaffold
por: Totrov, M, et al.
Publicado: (2009)

Pilot trial of oral therapeutic HIV vaccine, V-1 Immunitor, on HIV and HIV/HCV patients in Russia
por: Bourinbaiar, Aldar, et al.
Publicado: (2010)

P28 - Wells’ syndrome (or Eosinophilic Cellulitis) – a case report
por: Koutsalitis, Dimitrios, et al.
Publicado: (2014)

P14-09. Use of HIV rapid tests for assessment of persistence of vaccine induced antibodies among HIV vaccine recipients
por: Karita, E, et al.
Publicado: (2009)

P28. Efficient CD19-positive leukaemia cell lysis mediated by a T cell-recruiting triple body a[19-3-19]
por: Roskopf, CC, et al.
Publicado: (2014)

No impact of IL28B polymorphisms on liver enzymes in patients coinfected with HIV and HCV
por: Fernández-Montero, JV, et al.
Publicado: (2010)

Design and development of a new lentiviral based anti-HIV therapeutic vaccine
por: Rodriguez, M, et al.
Publicado: (2012)

P19-16. Potential of an HIV-1 Tat fusion protein expressed in tomato as a plant-based HIV vaccine
por: Cueno, ME, et al.
Publicado: (2009)

HIV-1 acetylated integrase is targeted by KAP1 (TRIM28) to inhibit viral integration
por: Allouch, Awatef, et al.
Publicado: (2009)

High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece
por: Panagopoulos, P, et al.
Publicado: (2010)

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials
por: Morgan, C, et al.
Publicado: (2012)

P19-54 LB. Interrogating the membrane-proximal external region (MPER) of HIV-1 gp140
por: Jeffs, S, et al.
Publicado: (2009)

P15-23. Community engagement strategies in the Canadian HIV vaccine initiative
por: Milsom, P, et al.
Publicado: (2009)

P15-27. Community involvement and ethics in HIV vaccine trial in Nigeria
por: Adeyemi, AO, et al.
Publicado: (2009)

P05-12. A computationally designed immunogen elicits potent anti-V3 neutralizing antibodies
por: Carrico, CT, et al.
Publicado: (2009)

P19-10. Induction of dendritic cell maturation by a liposomally-delivered multivalent HIV vaccine
por: Azizi, A, et al.
Publicado: (2009)

P19-39. Vaccibodies: a novel vaccine strategy for HIV that target viral antigens to APC
por: Øynebråten, I, et al.
Publicado: (2009)

P19-21. Sequence variability in the crown of the V3 loop of the HIV-1 envelope is clustered within a small 3D structural zone
por: Almond, D, et al.
Publicado: (2009)

P19-26. Directing macaque immune responses with an anti-dendritic cell HIV Gag p24 fusion protein vaccine
por: Martinon, F, et al.
Publicado: (2009)

P19-45. Development of a therapeutic HIV vaccine comprised of autologous dendritic cells loaded with a mixture of lipopeptide HIV antigens
por: Cobb, AJ, et al.
Publicado: (2009)

An impact of HIV disease severity on in vitro CD4+ T cell expansion using anti-CD3/28 coated magnetic beads for being used as an alternative treatment in HIV infected patients
por: Onlamoon, Nattawat, et al.
Publicado: (2014)

P19-05. Use of autologous apoptotic pseudovirus infected cells for vaccination against HIV, evaluation in macaques
por: Koopman, G, et al.
Publicado: (2009)

P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
por: Zhang, C, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_dgec87fi3cpqkoekf44flfmg0g